Valine

• 

  Subject Areas on Research

  • A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. 
  • A circuit model for saccadic suppression in the superior colliculus. 
  • A grease-gap method for studying the excitatory amino acid pharmacology of CA1 hippocampal pyramidal cells. 
  • A high proportion of ADA point mutations associated with a specific alanine-to-valine substitution. 
  • A replicated molecular genetic basis for subtyping antisocial behavior in children with attention-deficit/hyperactivity disorder. 
  • A single valine residue plays an essential role in peripherin/rds targeting to photoreceptor outer segments. 
  • A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents. 
  • A91V is a polymorphism in the perforin gene not causative of an FHLH phenotype. 
  • Activation of human plasminogen by urokinase. Partial characterization of a pre-activation peptide. 
  • Adhesion of Blood Plasma Proteins and Platelet-rich Plasma on l-Valine-Based Poly(ester urea). 
  • Alanine to valine substitutions in the pore helix IIIP1 and linker-helix IIIL45 confer cockroach sodium channel resistance to DDT and pyrethroids. 
  • Allelic differences in the brain-derived neurotrophic factor Val66Met polymorphism in late-life depression. 
  • Amino acid-based Poly(ester urea) copolymer films for hernia-repair applications. 
  • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. 
  • Assessing bioequivalence using genomic data. 
  • BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis. 
  • BDNF Val66Met genotype and 6-month remission rates in late-life depression. 
  • Blockade of hyperbaric oxygen induced seizures by excitatory amino acid antagonists. 
  • Brain-derived neurotrophic factor (BDNF) Val66Met and adulthood chronic stress interact to affect depressive symptoms. 
  • Brain-derived neurotrophic factor val66met polymorphism and hippocampal activation during episodic encoding and retrieval tasks. 
  • Branched-chain α-ketoacids are preferentially reaminated and activate protein synthesis in the heart. 
  • COMT and anxiety and cognition in children with chromosome 22q11.2 deletion syndrome. 
  • COMT val108/158 met genotype affects neural but not cognitive processing in healthy individuals. 
  • COMT158 polymorphism and hostility. 
  • Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. 
  • Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. 
  • Characterization of excitatory amino acid receptors expressed by embryonic chick motoneurons in vitro. 
  • Clamp subunit dissociation dictates bacteriophage T4 DNA polymerase holoenzyme disassembly. 
  • Concerning the mechanism of FSH action: rapid stimulation of testicular synthesis of nuclear RNA. 
  • Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase. 
  • Cytocidal amino acid starvation of Saccharomyces cerevisiae and Candida albicans acetolactate synthase (ilv2{Delta}) mutants is influenced by the carbon source and rapamycin. 
  • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 
  • Diagnosis and Treatment of Acute Retinal Necrosis: A Report by the American Academy of Ophthalmology. 
  • Differential actions of diazepam and zolpidem in basolateral and central amygdala nuclei. 
  • Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. 
  • Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. 
  • Effects of valsartan and valeryl 4-hydroxy valsartan on human platelets: a possible additional mechanism for clinical benefits. 
  • Estrogen-induced changes in translation, and specific messenger RNA levels during oviduct differentiation. 
  • Estrogen-induced synthesis of ovalbumin messenger RNA and its translation in a cell-free system. 
  • Fast endocytosis is inhibited by GABA-mediated chloride influx at a presynaptic terminal. 
  • Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. 
  • Further insights into quinone cofactor biogenesis: probing the role of mauG in methylamine dehydrogenase tryptophan tryptophylquinone formation. 
  • Genetic vulnerability to affective psychopathology in childhood: a combined voxel-based morphometry and functional magnetic resonance imaging study. 
  • Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Hemoglobin Raleigh (beta1 valine replaced by acetylalanine). Structural and functional characterization. 
  • Herpes simplex virus hepatitis after renal transplantation. 
  • Impact of BDNF Val66Met and 5-HTTLPR polymorphism variants on neural substrates related to sadness and executive function. 
  • Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. 
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). 
  • Improved excitation pulse bandwidths using shaped pulses, with application to heteronuclear half filters in macromolecular NMR. 
  • Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. 
  • Isolation of polyribosomes and characteristics of an amino acid-incorporation system from the liver of a primate (Papio papio). 
  • Isolation of protein factors from oviduct polysomes which stimulate protein synthesis. 
  • Left ventricular assessment in myocardial infarction: the VALIANT registry. 
  • Living related versus deceased donor liver transplantation for maple syrup urine disease. 
  • Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. 
  • Manganese superoxide dismutase Ala-9Val polymorphism and risk of breast cancer in a population-based case-control study of African Americans and whites. 
  • Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case-control study. 
  • Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). 
  • Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. 
  • NMDA antagonists differentiate epileptogenesis from seizure expression in an in vitro model. 
  • Neural origin of evoked potentials during thalamic deep brain stimulation. 
  • Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. 
  • Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors. 
  • Orientation of LamB signal peptides in bilayers: influence of lipid probes on peptide binding and interpretation of fluorescence quenching data. 
  • Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. 
  • Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. 
  • Potentially functional single nucleotide polymorphisms in the core nucleotide excision repair genes and risk of squamous cell carcinoma of the head and neck. 
  • Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. 
  • Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. 
  • Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. 
  • Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. 
  • Protein biosynthesis in the testis. V. Concerning the mechanism of stimulation by follicle-stimulating hormone. 
  • Protein bisoynthesis in the testis. IV. Isolation and properties of polyribosomes. 
  • Quantifying the Impact of Atrial Fibrillation on Heart Failure-Related Patient-Reported Outcomes in the Utah mEVAL Program. 
  • Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. 
  • Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. 
  • Recommendations for the management of herpes zoster. 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. 
  • Seven novel mutations in the adenosine deaminase (ADA) gene in patients with severe and delayed onset combined immunodeficiency: G74C, V129M, G140E, R149W, Q199P, 462delG, and E337del. Mutations in brief no. 142. Online. 
  • Stimulation of cell-free polypeptide synthesis by a protein fraction extracted from chick oviduct polyribosomes. 
  • Substitution of an extracellular cysteine in the beta 2-adrenergic receptor enhances agonist-promoted phosphorylation and receptor desensitization. 
  • Systematic collection of patient-reported outcomes in atrial fibrillation: feasibility and initial results of the Utah mEVAL AF programme. 
  • The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults. 
  • The NMDA receptor antagonist 2-amino-5-phosphonovalerate blocks stimulus train-induced epileptogenesis but not epileptiform bursting in the rat hippocampal slice. 
  • The brain-derived neurotrophic factor VAL66MET polymorphism and cerebral white matter hyperintensities in late-life depression. 
  • The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • The molecular basis for ligand specificity in a mouse olfactory receptor: a network of functionally important residues. 
  • The transcription factor calcium-response factor limits NMDA receptor-dependent transcription in the developing brain. 
  • Therapeutic implications of high-dose angiotensin receptor blocker monotherapy in mild-to-moderate hypertensive patients. 
  • Thrombospondin-4 contributes to spinal sensitization and neuropathic pain states. 
  • Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults. 
  • Treatment of sudden sensorineural hearing loss with systemic steroids and valacyclovir. 
  • Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). 
  • Valsartan inhibits platelet activity at different doses in mild to moderate hypertensives: Valsartan Inhibits Platelets (VIP) trial. 
  • Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology